其它产品项目整合

项目整合的本质是一项集合成方法学、反应工程学与过程分析技术于一体的系统工程。其核心逻辑可以概括为以下几点：源头优选：利用如N-硝胺化学等底层方法学突破，从分子层面颠覆传统高成本、高污染路线。过程强化：依托连续流技术，攻克有机金属试剂应用、光化学反应放大等“不可能”任务，实现高危工艺的本质安全。系统集成：整合“反应-淬灭-分离”全流程，利用微流控与在线分析技术，消除批次间的差异，实现药品制造的连续化与智能化。当前，中间体工艺研发正在经历从“经验驱动”向“数据驱动”的转变。AI辅助路线设计、自动化高通量筛选与连续制造平台的结合，将使得“分子结构与最优工艺路径”之间的映射关系逐渐清晰。未来的竞争优势，将属于那些能够将底层化学创新与先进工程技术进行无缝整合的研发体系。
备注: 根据相关法律法规, 本站点不显示有法律约束管制的产品, 如有遗漏, 请自行鉴别,或提交我们及时更新撤除.
如有产品相关项目调研推广服务, 请致函联系我们

客户展示

其它产品项目整合

Streptovaricin CAS Registry Number: 1404-74-6 链伐立星

Additional Names: Streptovarycin
Literature References: A complex of ansamycin antibiotics consisting of streptovaricins A, B, C, D, E, F, G, J and K of which streptovaricin C is the major component. Isolation from Streptomyces spectabilis: Siminoff et al., Am. Rev. Tuberc. Pulm. Dis. 75, 576 (1957); Whitfield et al., ibid. 584; and resolution of components: Dietz et al., US 3116202 (1963 to Upjohn). Characterization of complex: Rinehart et al., Chem. Commun. 1974, 861. Preliminary structural studies: Rinehart et al., J. Am. Chem. Soc. 88, 3149, 3150 (1966); 90, 6241 (1968); Rinehart et al., ibid. 93, 6273 (1971). Revised structure of streptovaricin C: Sasaki et al., J. Antibiot. 25 68 (1972); Rinehart, Antosz, ibid. 71. Activity studies: Quintrell, McAuslan, J. Virol. 6, 485 (1970); Tan, McAuslan, Biochem. Biophys. Res. Commun. 42, 230 (1971); Carter et al., Nature New Biol. 232, 212, 214 (1971). Biosynthetic study: P. V. Deshmukh et al., J. Am. Chem. Soc. 98, 870 (1976). 13C-NMR studies: K. B. Kakinuma et al., J. Org. Chem. 41, 1358 (1976). Synthesis of a key intermediate for the total synthesis of streptovaricin A: P. A. McCarthy, Tetrahedron Lett. 23, 4199 (1982). Synthesis of the naphthalene core of streptovaricin D: B. M. Trost, W. H. Pearson, ibid. 24, 269 (1983). Review of the chemistry of streptovaricins: K. L. Rinehart et al., Fortschr. Chem. Org. Naturst. 33, 231-307 (1976).

d-Verbenone CAS Registry Number: 18309-32-5 (1R,5R)-4,6,6-三甲基双环[3.1.1]庚-3-烯-2-酮

CAS Name: (1R)-4,6,6-Trimethylbicyclo[3.1.1]hept-3-en-2-one
Additional Names: (1R,5R)-(+)-2-pinen-4-one
Percent Composition: C 79.95%, H 9.39%, O 10.65%
Literature References: A constituent of Spanish verbena oil (from Verbena triphylla L., Verbenaceae): Kerschbaum, Ber. 33, 885 (1900). Prepn from a-pinene: Bain, Gary, US 2911442 (1959 to Glidden). Structure: Blumann, Zeitschel, Ber. 46, 1178 (1913); Weinhaus, Schumm, Ann. 439, 20 (1924). Absolute configuration: Hurst, Whitham, J. Chem. Soc. 1960, 2864. Review: J. L. Simonsen, The Terpenes vol. II (University Press, Cambridge, 2nd ed., 1949) p 232-239.

Chrysanthenone CAS Registry Number: 473-06-3

CAS Name: 2,7,7-Trimethylbicyclo[3.1.1]heptan-6-one
Additional Names: 2-pinen-7-one
Percent Composition: C 79.95%, H 9.39%, O 10.65%
Literature References: A constituent of the essential oil of Chrysanthemum indicium L., also extracted from C. sinense Sabin, Compositae. Prepared by photochemical rearrangement of l- or d-verbenone, q.v.: Hurst, Whitham, J. Chem. Soc. 1960, 2864; Erman, J. Am. Chem. Soc. 89, 3828 (1967); Schuster, Widman, Tetrahedron Lett. 1971, 3571. Structure: Kotake, Nonaka, Ann. 607, 153 (1957); Blanchard, Chem. Ind. (London) 1958, 293. Chemistry: Erman, J. Am. Chem. Soc. 91, 779 (1969).

Tonin CAS Registry Number: 53414-68-9

Additional Names: b-Angiotensin I converting enzyme (formerly)
Literature References: A converting enzyme that differs from renin, q.v., in its ability to form angiotensin II directly from angiotensinogen by cleaving the Phe-His bond; it can also convert angiotensin I to angiotensin II. Its presence was discovered in rat submaxillary glands: R. Boucher et al., Hypertension 72, J. Genest, E. Koiw, Eds. (Springer-Verlag, New York, 1972) p 512; eidem, Circ. Res. Suppl. I, 203 (1974). Purification and characterization: S. Demassieux et al., Can. J. Biochem. 54, 788 (1976). Crystal data: K. Hayakawa et al., J. Mol. Biol. 123, 107 (1978). Radioimmunoassay: J. Gutkowska et al., Can. J. Biochem. 56, 769 (1978). Purification by affinity chromatography: M. Ikeda et al., Hypertension 3, 81 (1981); by gel permeation and HPLC: C. Lazure et al., Anal. Biochem. 125, 406 (1982). Isoln using chromatofocusing: E. S. P. Cheng, B. J. Morris, ibid. 126, 295 (1982). N-Terminal amino acid sequence of rat tonin: N. G. Seidah et al., Can. J. Biochem. 56, 920 (1978). Substrate specificity studies: eidem, Proc. Am. Peptide Symp. 6th, E. Gross, J. Meienhofer, Eds. (Pierce Chem. Co., Rockford, Ill., 1979) p 921; M. Chretien et al., FEBS Lett. 113, 173 (1980). Formation of angiotensin II by tonin from partially purified human angiotensinogen: C. Grise et al., Can. J. Biochem. 59, 250 (1981). Pressor effect in anephric animals: E. L. Schiffrin et al., Can. J. Physiol. Pharmacol. 59, 864 (1981). Sequence homologies between tonin and other peptides: C. Lazure et al., Nature 292, 383 (1981). Immunohistochemical study: T. B. Oerstavik et al., J. Histochem. Cytochem. 30, 1123 (1982). Role as renin activator: J. Gutkowska et al., Can. J. Biochem. 60, 843 (1982). Role in exptl hypertension: R. Garcia et al., Hypertension, Int. Symp., 3rd, H. Villarreal, Ed. (Wiley, New York, 1981) p 79. Reviews: R. Boucher et al., Circ. Res. Suppl. II, 26-29 (1977); R. Boucher, J. Genest, Endocrine Functions of the Brain, M. Motta, Ed. (Raven Press, New York, 1980) pp 373-384; J. Genest, Heterogeneity of Renin and Renin Substrate, M. P. Sambhi, Ed. (Elsevier, New York, 1981) pp 11-24.

Ancitabine CAS Registry Number: 31698-14-3 安西他滨

CAS Name: [2R-(2a,3b,3ab,9ab)]-2,3,3a,9a-Tetrahydro-3-hydroxy-6-imino-6H-furo[2',3':4,5]oxazolo[3,2-a]pyrimidine-2-methanol
Additional Names: 2,2'-anhydro-(1b-D-arabinofuranosyl)cytosine; 2,2'-...
Literature References: A cytostatic agent and intermediate in the synthesis of cytarabine, q.v. Prepn of the hydrochloride: E. R. Walwick et al., Proc. Chem. Soc. London 1959, 84; T. Y. Shen, W. V. Ruyle, US 3463850 (1969 to Merck Co.); E. K. Hamamura et al., J. Med. Chem. 19, 654 (1976). General pharmacological properties: H. Hirayama et al., Oyo Yakuri 6, 1259 (1972), C.A. 79, 49175f (1973). Metabolism: D. H. W. Ho, Drug Metab. Dispos. 1, 752 (1973). Biochemical study: idem, Biochem. Pharmacol. 23, 1235 (1974). Pharmacokinetic study: H. S. Chen, J. F. Gross, Cancer Chemother. Pharmacol. 2, 85 (1979). Clinical studies: J. Z. Finklestein et al., Cancer Treat. Rep. 63, 1331 (1979); T. Miale et al., ibid. 1913. Toxicity studies: K. Sugihara et al., Oyo Yakuri 8, 1469 (1974); H. Hirayama et al., ibid. 1693, C.A. 83, 71766, 37747 (1975). HPLC study: V. Reichelova et al., J. Chromatogr. 588, 147 (1991).

Apo- b -erythroidine CAS Registry Number: 478-85-3

CAS Name: 4,5,7,8,9,12-Hexahydro-11H-pyrano[3,4-d]pyrrolo[3,2,1-jk][1]benzazepin-11-one
Percent Composition: C 74.67%, H 6.27%, N 5.80%, O 13.26%
Literature References: A degradation product of b-erythroidine. Prepd by heating b-erythroidine to 120° with phosphoric or sulfuric acid: Sauvage et al., Science 109, 627 (1947); by reacting b-erythroidine with concd hydrobromic acid at 100°: Koniuszy, Folkers, J. Am. Chem. Soc. 73, 333 (1951). Synthesis and structure: Blake et al., J. Am. Chem. Soc. 87, 1397 (1965).

Pantolactone CAS Registry Number: 599-04-2 D-(-)-泛酰内酯

CAS Name: Dihydro-3-hydroxy-4H-dimethyl-2(3H)-furanone
Additional Names: pantoic acid g-lactone; pantoyl lactone; pantoic lactone; 2,4-dihydroxy-3,3-dimethylbutyric acid g-lactone; a-hydroxy-b,...
Literature References: A degradation product of pantothenic acid from liver: Williams, Major, Science 91, 246 (1940). Important intermediate in the synthesis of pantothenic acid. May be prepd by condensing isobutyraldehyde with formaldehyde yielding a,a-dimethyl-b-hydroxypropionaldehyde which is condensed with hydrocyanic acid in the presence of calcium chloride to form racemic pantolactone. Various modifications of this procedure exist: Glaser, Monatsh. Chem. 25, 46 (1904); Stiller et al., J. Am. Chem. Soc. 62, 1785 (1940); Reichstein, Grüssner, Helv. Chim. Acta 23, 650 (1940); Carter, Ney, J. Am. Chem. Soc. 63, 312 (1941). Vast patent literature, e.g., Beckmann et al.; Klein, US 2967869 and US 3024250 (1961, 1962, both to Nopco).

Pseudomorphine CAS Registry Number: 125-24-6 伪吗啡(吗啡杂质)

CAS Name: (5'a,6'a)-7,7',8,8'-Tetradehydro-4,5:4',5'-diepoxy-17,17'-dimethyl-[2,2'-bimorphinan]-3,3',6,6'-tetrol
Additional Names: 2,2'-bimorphine; pseudomorphine (C34 alkaloid)
Percent Comp...
Literature References: A dimolecular base formed by the gentle oxidation of morphine in alkaline soln. Refs: Broockmann, Polstorff, Ber. 13, 88 (1880); Bentley, Dyke, J. Chem. Soc. 1959, 2574. Review and bibliography: K. W. Bentley, The Chemistry of the Morphine Alkaloids (Oxford, 1954) p 54.

Bismuth Sodium Triglycollamate CAS Registry Number: 5798-43-6 3,6-二(丙烷-2-基)哌嗪-2,5-二酮

CAS Name: Nitrilotriacetic acid bismuth complex sodium salt
Trademarks: Bistrimate (SM P)
Percent Composition: C 25.23%, H 2.47%, Bi 18.29%, N 4.90%, Na 14.09%, O 35.01%
Literature References: A double salt of sodium bismuthyl triglycollamate and disodium triglycollamate. Prepn: Lehman, Sproull, US 2348984 (1944).

Milbemycins CAS Registry Number: 51570-36-6

Additional Names: Antibiotic B-41
Literature References: A family of novel macrolide antibiotics with insecticidal and acaricidal activity; structurally related to avermectin, q.v., aglycones. Isoln from Streptomyces hygroscopicus subsp. aureolacrimosus and properties: A. Aoki et al., DE 2329486; eidem, US 3950360 (1973, 1976 both to Sankyo); of a1-a10, b1-b3, D-H: Y. Takiguchi et al., J. Antibiot. 33, 1120 (1980). Isoln and properties of D-H: Y. Takiguchi et al., J. Antibiot. 36, 502 (1983); of J and K: M. Ono et al., ibid. 509. Structures of milbemycins a1-a10, b1: M. Kurabayashi et al., 18th Symp. Chem. Natural Products (Kyoto, 1974) nos. 309-316; of b1-b3: H. Mishima et al., Tetrahedron Lett. 1975, 711; of D-H, J, K: H. Mishima et al., J. Antibiot. 36, 980 (1983). Total synthesis of (±)-milbemycin b3: A. B. Smith et al., J. Am. Chem. Soc. 104, 4015 (1982); of the (+)-form: D. R. Williams et al., ibid. 4708. Prepn of milbemycins from avermectins: H. Mrozik et al., Tetrahedron Lett. 1983, 5333. Total synthesis studies of D: M. T. Crimmins et al., ibid. 28, 3651 (1987). Prophylactic use of milbemycin D against Dirofilaria immitis infection in dogs: M. Tagawa et al., Jpn. J. Vet. Sci. 47, 787 (1985). Toxicity data: N. Matsunuma et al., Sankyo Kenkyusho Nempo 35, 71 (1983), C.A. 101, 32870d (1984). Review of syntheses: T. Blizzard et al., in Recent Prog. Chem. Synth. Antibiotics, G. Lukacs, M. Ohno, Eds (Springer-Verlag, Berlin, 1990) pp 66-102. Review of structure-activity relationships: W. L. Shoop et al., Vet. Parasitol. 59, 139-156 (1995).